{
    "clinical_study": {
        "@rank": "131049", 
        "arm_group": {
            "arm_group_label": "SOX sequential S-1", 
            "arm_group_type": "Experimental", 
            "description": "4-6 cycles of SOX followed by S-1 monotherapy until disease progression"
        }, 
        "brief_summary": {
            "textblock": "This is an exploratory, single-armed, open label study on the efficacy and safety of\n      sequential S-1 therapy after SOX in unresectable metastatic or locally advanced biliary\n      system or periampullary cancer or pancreatic cancer patients. The primary endpoint is\n      Objective response rate and secondary endpoint is progression free survival , overall\n      survival ,1 year survival rate and safety."
        }, 
        "brief_title": "SOX Sequential S-1 in Advanced Biliary Tract Carcinoma\uff08BTC\uff09and Pancreatic Cancer", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Biliary Tract Cancer", 
            "Periampullary Adenocarcinoma", 
            "Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms", 
                "Biliary Tract Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written Informed consent\n\n          -  Male or female patients >=18 years old\n\n          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma\n\n          -  No previous treatment is allowed including chemotherapy, radiotherapy,immunotherapy\n             or others.\n\n          -  In case the patient received adjuvant therapy before, enrollment is allowed if the\n             adjuvant therapy does not contain L-OHP or S-1 and at the same time, the last day of\n             chemotherapy is \u2265180 days before screening.\n\n          -  Target lesion more than 1cm in diameter by enhanced CT or MRI 21 days before\n             enrollment\n\n          -  The laboratory parameter meets the following criteria 7 days before enrollment\n\n               -  Hemoglobin \u226590g/L\n\n               -  Absolute neutrophil count\u22651.5\u00d710^9/L, platelets 100\u00d710^9/L\uff1b\n\n               -  ALT and AST\u22642.5 ULN(in case of the patients with liver metastasis,ALT and\n                  AST\u22645.0 ULN)\n\n               -  ALP \u22642.5 ULN (in case of the patients with liver metastasis,\u22645.0 ULN)\n\n               -  Total Serum bilirubin \u22641.5 ULN\n\n               -  Serum creatinine \u22641.0 ULN\n\n               -  serum albumin(ALB)\u226530g/L\uff1b\n\n          -  can tolerate oral drug administration\uff1b\n\n          -  KPS \u226570\n\n          -  Estimated survival \u226590 days\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test\n             within 7 days of enrollment and must be willing to use adequate methods of\n             contraception during the study and for 30 days after last study durg administration.\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to 5-HT3 antagonist and hypersensitivity to the other treatment\n             agents including irinotecan, cisplatin and octreotide lar\n\n          -  Any participation in trials simultaneously or 4 weeks before screening.\n\n          -  15 days prior to enrollment, received a blood transfusion, blood products and\n             hematopoietic growth factors such as G-CSF.\n\n          -  Undergone major surgery \u2264 4 weeks prior to starting study drug or who have not\n             recovered from side effects of such surgery.\n\n          -  Uncontrolled severe diarrhea\n\n          -  Uncontrolled active infection (fever \u226538 degrees due to infection)\n\n          -  S-1 oral drug administration difficulty due to difficulty swallowing, complete or\n             incomplete digestive tract obstruction, gastrointestinal active bleeding,\n             perforation;\n\n          -  severe hepatopathy including active hepatitis and hepatic cirrhosis, renal\n             dysfunction, severe pulmonary diseases including interstitial pneumonia, pulmonary\n             fibrosis and severe pulmonary emphysema, uncontrolled diabetes, hypertension and\n             other chronic systematic diseases.\n\n          -  Chronic treatment with steroids.(In case of the patients with short-term use of\n             steroids, the enrollment is permitted if the administration is stopped 2 weeks before\n             screening.)\n\n          -  confirmed or suspected CNS metastasis\n\n          -  the history of peripheral nervous system impairment, obvious mental disorder or CNS\n             impairment\n\n          -  clinically significant heart disease, including congestive heart failure, symptomatic\n             coronal heart disease, arrythmia uncontrolled by medication and acute myocardial\n             infarction or cardiac insufficiency within 6 months before screening\n\n          -  Drainage of pleural effusion, peritoneal effusion and pericardial effusion\n\n          -  pregnant women or women in lactation period\n\n          -  Fertile male or women of child-bearing potential refuse to take highly effective\n             methods of birth control\n\n          -  Incidence of other second primary malignant tumors within 5 years, except for cured\n             basal cell carcinoma and cervical carcinoma in situ.\n\n          -  patients of legal incapacity or who have the potential of influence the whole trial\n             due to medical or ethic reasons.\n\n          -  Other patients who are not eligible to the trial under investigators' discretion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811277", 
            "org_study_id": "SOX-S-1 BTC"
        }, 
        "intervention": {
            "arm_group_label": "SOX sequential S-1", 
            "description": "4-6 cycles SOX followed by S-1 monotherapy until disease progression\nS-1: 40~60mg bid\uff0cpo, d1~14 \uff08S-1\uff1aBSA <1.25m2, 40mg bid, 1.25m2\u2264BSA\u22641.5m2,50mg bid, BSA>1.5m2, 60mg bid\uff09 oxaliplatin\uff1a130mg/m2\uff0civ drip for 2h\uff0cd1", 
            "intervention_name": "SOX sequential S-1", 
            "intervention_type": "Drug", 
            "other_name": "S-1/oxaliplatin"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxaliplatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "palliative chemotherapy", 
            "ORR", 
            "PFS", 
            "OS", 
            "safety", 
            "advanced Biliary Tract Carcinoma"
        ], 
        "lastchanged_date": "March 13, 2013", 
        "location": {
            "contact": {
                "email": "lin100@medmail.com.cn", 
                "last_name": "Lin Shen, Prof.", 
                "phone": "+86 10 88196175"
            }, 
            "contact_backup": {
                "email": "xiaotong10241@sina.com", 
                "last_name": "Jie Li, Prof.", 
                "phone": "+86 10 88196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "Beijing Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer", 
        "overall_contact": {
            "email": "lin100@medmail.com.cn", 
            "last_name": "Lin Shen, Prof.", 
            "phone": "+86 10 88196175"
        }, 
        "overall_contact_backup": {
            "email": "xiaotong10241@sina.com", 
            "last_name": "Jie Li, Prof.", 
            "phone": "+86 10 88196561"
        }, 
        "overall_official": {
            "affiliation": "Beijing Cancer Hospital", 
            "last_name": "Lin Shen, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is objective response rate,which equals CR+PR.", 
            "measure": "Objective response rate for SOX sequential S-1", 
            "safety_issue": "No", 
            "time_frame": "1 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811277"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Head of GI Cancer department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "PFS means that from the first dose of treatment drug to disease progression or death or lost, the follow-up visit will be performed every 6 weeks till progression or death or lost", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "the follow-up visit of survival will be performed every 3 months till 1 year", 
                "measure": "1 year survival rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "participants will be followed for the duration of hospital stay, an expected average of 3 weeks", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "collaborator": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2010"
    }
}